Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.57 |
| ▸ | EDNRA | P25101 | 3/20 | 0.48 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902232 | 0.88 | KDM1A (0.47) | ABCG2DHFRCYP1A2LMNAMAPT | |
| SCHEMBL15397407 | 0.87 | ABCG2 (0.67) | ABCG2EDNRADHFRCYP1A2CYP3A4 | |
| SCHEMBL902453 | 0.83 | DHFR (0.44) | ABCG2DHFRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL902614 | 0.79 | DYRK1A (0.43) | ABCG2EDNRADHFRLMNAKDM4E | |
| SCHEMBL15397420 | 0.78 | KDM1A (0.50) | ABCG2DHFRCYP1A2LMNAMAPT | |
| SCHEMBL901828 | 0.76 | KDM1A (0.50) | ABCG2DHFRCYP1A2MAPK1LMNA | |
| SCHEMBL901721 | 0.75 | TOP2A (0.47) | ABCG2MAPTKDM4ETSHRHTT | |
| SCHEMBL18252667 | 0.74 | EDNRA (0.49) | ABCG2EDNRADHFRCYP3A4EDNRB | |
| SCHEMBL902724 | 0.73 | SMN1; SMN2 (0.45) | ABCG2CYP2C9CYP2D6LMNAMAPT | |
| SCHEMBL15397415 | 0.71 | DHFR (0.41) | DHFRCYP1A2NR1I3MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2621929-A1 | NOVEL ACRIDINE DERIVATIVES | Pharminox Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | TERT, NAT10, POT1 | ABCG2 3413/4885EDNRA 3512/4885DHFR 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.